SR34006 Compared to Vitamin K Antagonist (VKA) in the Treatment of Pulmonary Embolism
The Van Gogh-PE Trial, a Multicenter, International, Randomized, Open-Label, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous SR34006 With the Combination of (LMW)Heparin and Vitamin K Antagonist (VKA) in the Treatment of Acute Symptomatic Pulmonary Embolism
Sponsor: Sanofi
A PHASE3 clinical study on Pulmonary Embolism, this trial is completed. The trial is conducted by Sanofi and has accumulated 6 data snapshots since 2003. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE3
First recorded
Jun 2003
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Sanofi
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Akron, United States , Albuquerque, United States , Alexandria, United States , Alkmaar, Amersfoort, Amsterdam, Breda, Gouda, Groningen, Netherlands , Allentown, United States , Amarillo, United States , Arhus, Frederiksberg, Glostrup, Hillerod, Kobenhavn, Odense, Denmark , Armentieres, Besancon, Bethune, Brest, Chambray Les Tours, France , Augsburg, Berlin, Bochum, Dresden, Garmisch-Partenkirchen, Germany , Augusta, United States and 75 more locations